Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Press Releases
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Press Releases
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
September 20, 2023
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
September 18, 2023
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
September 11, 2023
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
September 5, 2023
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
August 30, 2023
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
August 28, 2023
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
August 28, 2023
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
August 21, 2023
Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results
August 14, 2023
Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373
July 24, 2023
‹
1
2
3
4
…
11
›
Close Menu
Company
Team
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact